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Objective: Gene transfer to experimental lung grafts has been shown to reduce
ischemia-reperfusion injury and acute rejection. The optimal delivery route should
produce high lung expression with no inflammation and minimal systemic expres-
sion. The goal of this study was to determine the optimal gene transfer route for use
in experimental lung transplantation.
Methods: F344 rats were injected with 2.9  1010 plaque-forming units of adeno-
virus vector encoding -galactosidase through intratracheal, intravenous, intraperi-
toneal, or intramuscular delivery routes and killed 48 hours later. Gene expression
was measured by means of enzyme-linked immunosorbent assay.
Results: Intratracheal delivery produces significantly greater gene expression in the
lung (75,350  47,288 pg/100 g of protein, P  .001 vs intravenous, intraperi-
toneal, and intramuscular routes) and minimal systemic expression (nonsignificant
in serum, kidney, liver, spleen, and muscle vs that seen in control animals, P .016
for heart). Immunohistochemistry staining showed -galactosidase expression in the
bronchial epithelium of lungs transfected through the intratracheal route with mild
inflammation.
Conclusions: Intratracheal gene transfer provides significant expression in the lung
with mild to no inflammation and minimal systemic expression. This delivery strategy
has tremendous potential in experimental lung transplant models to reduce ischemia-
reperfusion injury and acute allograft rejection and should be investigated further.
Gene therapy has emerged as a potential therapeutic modality forthe treatment of a wide variety of diseases, including ischemia-reperfusion injury and acute allograft rejection in transplanta-tion.1,2 In experimental donor lung grafts, gene transfection hasbeen shown to reduce these acute lung injuries.3,4Gene therapy requires a vector to deliver therapeutic genetic
material to the target cell.5 Adenoviral vectors possess high transfection efficiency
and can be purified and concentrated to high titers.6 Unfortunately, adenovirus-
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mediated transfection causes mild-to-moderate host inflam-
mation and elicits a strong host immune response, limiting
the duration of expression and effective retransfection.7,8
Several different delivery routes exist for gene therapy.
However, the optimal delivery route in lung transplantation
has not been determined. The preferred delivery strategy
would produce high pulmonary expression with no inflam-
mation and minimal systemic expression. Intravenous or
intraperitoneal administration of adenoviral vectors leads to
successful transfection, but systemic toxicity remains a con-
cern.9,10 Other studies indicate that intratracheal and intra-
muscular transfection hold the most promise for reducing
ischemia-reperfusion injury and acute rejection in lung
transplantation.11-13 Our laboratory has shown that trans-
gene expression is effective in ameliorating acute lung
injury with potentially fewer side effects.11,14,15 Further-
more, they possess future clinical potential.16 Intratracheal
transfection could be performed in the intensive care unit
before lung harvest, and a recipient could receive intramus-
cular transfection as soon as a donor is identified.
In this study different delivery routes were compared for
use in experimental lung transplantation to identify which
route provides maximal pulmonary expression with mini-
mal pulmonary inflammation and minimal systemic expres-
sion.
Materials and Methods
Animals
Male Fischer 344 rats (Harlan Sprague Dawley Inc, Indianapolis,
Ind) weighing between 250 and 300 g were used in all experi-
ments. All animal protocols were approved by the Animal Studies
Committee at Washington University. Animals received humane
care in compliance with the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical Research
and the “Guide for the Care and Use of Laboratory Animals”
prepared by the National Academy of Sciences and published by
the National Institutes of Health (National Institutes of Health
publication no. 85-23, revised 1996).
-Galactosidase Vector Delivery
Animals were injected with 2.9  1010 plaque-forming units of
adenovirus carrying the Escherichia coli LacZ gene encoding for
-galactosidase (-gal; n  6 for each group) by using the fol-
lowing routes: intravenous, intraperitoneal, intramuscular, or in-
tratracheal. The order of magnitude of 1010 of adenovirus was
chosen to ensure a higher level of expression when comparing the
different delivery routes. The adenovirus vector is replication
deficient, serotype 5, and driven by the constitutive cytomegalo-
virus promoter purchased from the Gene Therapy Center at the
University of North Carolina (Chapel Hill, NC).
Animals were anesthetized with halothane inhalation (1%-2%)
and subcutaneous injection of ketamine (25 mg/kg) and atropine
(30 mg/Kg) before injection. Intravenous injection was delivered
into the penile vein, and intramuscular injection was administered
to the gluteal muscle. Intratracheal administration was performed
through a 21-gauge catheter after intubation and mechanical ven-
tilation (model 683; Harvard Apparatus Co, South Natick, Mass)
maintained at room air with a 2.5-mL tidal volume and respiratory
rate of 65 breaths/min. A 21-gauge catheter was placed through the
14-gauge intubation catheter, and 250 L of vector was instilled
with the animal left-side down. The catheter was removed, and the
animal was ventilated for 30 seconds. The process was then
repeated with 250 L of vector with the animal right-side down,
and animals were recovered.
Animals were killed 48 hours later. This time point was chosen
because prior work in our laboratory indicated that adenoviral
-gal expression peaked at 48 hours after administration.11 An
intraperitoneal injection of 0.3 mL of pentobarbital (30 mg/kg) was
used for anesthesia. After intubation with a 14-gauge angiocatheter
by means of tracheotomy, mechanical ventilation, and systemic
heparinization (0.4 mL), a median laparosternotomy was per-
formed. Lungs were flushed with 20 mL of cold (4°C) saline
solution at 20 cm H2O pressure through the main pulmonary
artery, and then a systemic flush of 60 mL of cold saline solution
was administered through the left ventricle. The lungs, heart, liver,
spleen, kidneys, and gluteal muscle were harvested, frozen in
liquid nitrogen, and preserved at 70°C. Blood was collected and
centrifuged at 3200g for 15 minutes at 4°C. The plasma obtained
was also stored at 70°C.
Enzyme-Linked Immunosorbent Assay Assessment
-Gal tissue and serum expression was detected after the enzyme-
linked immunosorbent assay (ELISA; Boehringer Mannheim
GmbH, Mannheim, Germany) protocol. The optical density used
was 405 nm (corrected optical density of 490 nm) and standardized
to the total protein present in that sample. All tissues studied were
homogenized in lysis solution containing 100 mmol/L potassium
phosphate (pH 7.8), 0.2% triton X-100 with pepstatin A (5 g/
mL), and protease inhibitor (Complete mini-Tabs, Boehringer-
Mannheim). The homogenate was stored for 15 minutes at room
TABLE 1. Comparison of delivery route and tissue expression
Delivery route Lung Serum Muscle Liver Kidney Heart
Control 0 0 1 1 0 0 0.05 0.01 0.16 0.11 0 0
Intratracheal 75350 47288* 5.6 8.9 0.46 0.45 0.18 0.11 0.16 0.03 170 234*
Intravenous 0 0 409 507* 0.02 0.04 4668 3118* 0.14 0.05 0 0
Intraperitoneal 92 35* 21.3 31.5 0.73 0.85 1.4 1.4* 0.89 0.88 0.18 0.43
Intramuscular 0 0 12.3 6.1* 8.8 2.5* 0.27 0.30 0.09 0.02 0 0
Organ expression units are given in picograms per 100 g of protein, and serum expression is given in picograms per milliliter.
*P .05 compared with control values by using Mann-Whitney nonparametric analysis.
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temperature and then centrifuged at 15,000 rpm. The supernatant
was used to quantify -gal expression. Blood samples of 3 mL
were collected in ethylenediamine tetraacetic acid tubes and cen-
trifuged at 3200g for 10 minutes, and supernatants were frozen at
70°C until ELISA assessment. Each sample was standardized to
its total protein concentration by using the BCA protein assay kit
(Pierce, Rockford, Ill).
Histologic Assessment
Histologic Bluo-gal staining. Harvested organs were stained
with Bluo-gal solution, as previously described.17 Briefly, the
heart-lung blocks at harvest were flushed through the pulmonary
arterial trunk with phosphate-buffered saline (PBS) solution and
2% paraformaldehyde/0.2% glutaraldehyde solution supplemented
with 0.02% nonionic detergent (Nonidet P-40 [octylphenol-ethyl-
ene oxide]) and stored in 2% paraformaldehyde solution for 20
minutes. Systemic flush was through the left ventricle, with PBS
and 4% paraformaldehyde. After that, lungs and systemic organs
were flushed with PBS, followed by Bluo-gal. Finally, all organs
were immersed in Bluo-gal buffer for 24 hours at 37°C. The
Bluo-gal buffer consisted of 1 mg/mL Bluo-gal (5-bromo-indolyl-
-o-galactopyranoside; Gibco BRL, Gaithersburg, Md), 5 mmol/L
K3FeIII(CN)6, 5 mmol/L K4FeII(CN)6, 2 mmol/L MgCl2, 0.1%
Nonidet P-40, and PBS. After a final flush with PBS, organs were
fixed with 4% paraformaldehyde and paraffin embedded. Histo-
logic sections were counterstained with nuclear fast red.
Immunohistochemistry. Organs were flushed, as described
above, and then fixed with Histochoice (AMRESCO, Solon, Ohio)
or Bouin (Ricca Chemical Co, Arlington, Tex). The immunohis-
tochemistry was performed as previously described.18 Briefly,
after blocking for nonspecific sites, slides were incubated over-
night at 4°C with anti-E Coli -gal polyclonal rabbit antibody
(Polysciences, Warrington, Pa) at a 1:40 dilution in TNB buffer
(blocking reagent in 100 mmol/L Tris and 500 mmol/L NaCl, pH
7.4)/0.1% saponin. Slides were washed in Tris-buffered saline
solution/0.2% Triton X (100 mmol/L Tris and 500 mmol/L NaCl,
pH 7.4)/0.1% saponin. Slides were incubated with biotinylated
anti-rabbit IgG (Biogenex, San Roman, Calif). Finally, slides were
incubated for 30 minutes with streptavidin–alkaline phosphatase.
Chromogenic detection for -gal was performed with the Vector
NBT/BCIP Substrate Kit (Vector Laboratories, Inc, Burlingame
Calif) in 100 mmol/L Tris, pH 8.2, including 5 mmol/L levamisole
and counterstained with nuclear fast red.
The pattern of protein expression and degree of inflammation
were assessed by our pathologist (J.H.R.).
Statistical Analysis
One-way analysis of variance, Fisher least significant difference
test, and Mann-Whitney U test statistical analyses were used. Data
are expressed as means  SD. The funding agency (National
Institutes of Health) had no role in data interpretation.
Results
Intratracheal Route Provides Maximal Lung
Expression With Minimal Systemic Expression
-Gal gene expression in the lung was markedly increased
with intratracheal delivery compared with all other routes
and expression in control animals (P  .001 and P  .04,
Table 1). The order of magnitude of lung expression was
more than 1000 fold with intratracheal instillation compared
with the next highest level found with intraperitoneal deliv-
ery (75,350 vs 92, Table 1). Importantly, expression in the
serum, muscle, liver, kidney, heart, and spleen was negli-
gible, and only heart expression was found to be of statis-
tical significance (P  .016, Table 1). Histologically, stain-
ing of -gal is found in both lung (Figure 1) and heart
parenchyma (Figure 2, A). No staining was detected in the
spleen, kidney, liver, or muscle. Intratracheal delivery pro-
duces very high pulmonary expression with minimal sys-
temic expression.
Intramuscular Route Provides Significant Muscle and
Serum Expression
Muscle and serum expression were significantly elevated
with intramuscular injection compared with that seen in
control animals (P  .05), whereas lung, liver, kidney,
heart, and spleen expression were nearly identical to control
values (Table 1). The serum expression confirms that intra-
muscular injection effectively transfects muscle (Figure 2,
B) and produces its systemic effect through release into the
bloodstream.
Intravenous Route Provides Significant Systemic
Expression and Nondetectable Lung Expression
Liver, serum, and splenic expression were all significantly
elevated with intravenous administration (P .05, Table 1).
Liver expression was most dramatic. Expression in lung,
muscle, kidney, and heart was nondetectable and compara-
ble with that seen in control animals. Injection through the
penile vein results in liver and spleen transfection (Figure 2,
C and D) because these are the major organ beds seen as the
penile vein drains toward the heart. It is likely that the liver
clears the rest of the vector administered intravenously, and
Figure 1. Immunohistochemistry staining (blue) of lung tissue
after intratracheal delivery of -gal. (Original magnification
100.)
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therefore no expression was seen in the kidney, heart, and
lung. Similar to the intramuscular route, the serum expres-
sion supports the idea that intravenous injection effectively
transfects the liver (Figure 2, D) and produces its systemic
effect through release into the bloodstream.
Intraperitoneal Route Provides Both Systemic and
Lung Expression
Liver and lung expression, as determined by means of
ELISA, were significantly increased with intraperitoneal
injection versus control expression (P  .05, Table 1).
Splenic expression was not statistically significant, but
when examined histologically with Bluo-gal, there was
marked staining throughout (Figure 3, A). This likely re-
flects splenic uptake of -gal either hematogenously or
through lymphatic channels. Histologic assessment of the
liver shows only the surface of the liver staining for -gal.
No intraparenchymal staining is evident (Figure 3, B). In
examining the peritoneal lining in the abdomen, very strong
-gal staining is found (Figure 3, C). For the lung, we found
intraparenchymal -gal staining, as well as staining lining
the surface (Figure 3, D). Like the spleen, the intraparen-
chymal component probably represents either hematoge-
nous or lymphatic uptake, whereas the surface staining is
caused by direct exposure with the vector.
Discussion
Gene therapy has emerged as a new strategy for the treat-
ment of ischemia-reperfusion injury and acute allograft re-
jection in experimental lung transplantation models.1-4 The
lung is a particularly attractive organ for in vivo gene
therapy because it is directly accessible through the airway.
Furthermore, adenoviral vectors can efficiently transfect
nondividing or slowly dividing cells, such as the airway
epithelium.19,20
Gene transfer has used several different delivery routes,
including intravenous, intraperitoneal, intramuscular, and
intratracheal routes. Gene expression with adenoviral vec-
tors has been demonstrated in rodent lungs by means of
intratracheal instillation.21 A major advantage cited with
this route is the high level of lung expression with low or
undetectable levels in other organs.22,23 However, critical
shortcomings are that intratracheal injection is invasive,
leads to nonuniform distribution of instilled material, and is
associated with alveolar inflammation.22,23
The results of our study with intratracheal administration
show significant transgene expression in pulmonary epithe-
lial cells. A wide range in this expression exists (Table 1),
and this might reflect differences in the site of uptake, rate
of lung clearance, and variation in the ability of different
lung cell types to express the transgene.22 With respect to
Figure 2. -Gal expression (blue) by means of immunohistochemistry of heart tissue after intratracheal delivery (A),
immunohistochemistry of muscle after intramuscular delivery (B), immunohistochemistry of liver after intravenous
delivery (C), and Bluo-gal staining of spleen after intravenous delivery (D). (Original magnification 100.)
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cell types transfected, Mastrangeli and colleagues24 demon-
strated that ciliated, secretory, basal, and undifferentiated
airway epithelial cells were all transfected after intratracheal
installation of an adenoviral vector expressing -gal. The
airway epithelium was transfected in our study, including
type I and type II pneumocytes and a few ciliated cells.
There was no vascular endothelial transfection, and only
mild inflammation was found in the airways (Figure 1).
Adenovirus-mediated gene delivery is known to cause in-
flammation, and it is likely that our findings of only mild
inflammation 48 hours after transfection would show more
pronounced inflammation if examined at later time points.14
In addition, strategies exist that decrease adenoviral vector–
associated inflammation in the transplant setting, which
could be used in future studies.25
The first-generation adenoviral vector encoding -gal
did not transfect any pulmonary vascular endothelium
through either the intratracheal or intravenous routes. In
fact, no lung expression was found by using the intravenous
route. It is possible that minimal expression occurred but
that such levels were below the range of detection. In
contrast, Canonico and associates26 used plasmid-liposome
complexes and detected their protein in both the pulmonary
vascular endothelium and airway epithelium through intra-
venous injection. Similar to our findings, only the airway
epithelium and not the vascular endothelium was trans-
fected with intratracheal delivery. Zhu and coworkers27 also
found that the majority of cells present in the lung were
transfected after intravenous injection by using a chloram-
phenicol acetyltransferase–liposomal vector. This high-
lights the fact that different routes of gene delivery to the
lung and different vectors affect which target cells are
transfected.
The drawback with intravenous injection is the broad
spectrum of organs that might be undesirably transfected.
Expression has been detected in the spleen, liver, heart,
kidney, lymph nodes, thymus, uterus, ovary, skeletal mus-
cle, pancreas, bone marrow, stomach, small intestine, and
colon.27 We found substantial expression in the liver,
spleen, and serum after intravenous injection (Table 1).
However, expression in lung, muscle, kidney, and heart was
comparable with that seen in control animals. We believe
that penile vein injection results in liver and spleen trans-
fection (Figures 2, C and D) because these are the major
organ beds seen as the vein drains toward the heart. It is
possible that the liver clears the rest of the adenoviral
vector, and therefore no expression will be seen in the other
organs. We chose the penile route over the jugular route for
its ease of administration. However, in finding that the
penile route resulted in preferential liver uptake, future
studies might be directed at comparing whether lung and
Figure 3. -Gal expression in blue by means of Bluo-gal staining of spleen tissue after intraperitoneal delivery (A),
Bluo-gal staining of liver after intraperitoneal delivery (B), Bluo-gal staining of peritoneum after intraperitoneal
delivery (C), and immunohistochemistry of lung after intraperitoneal delivery (D). (Original magnification 100.)
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liver expression are influenced by the route of vector deliv-
ery.
Intraperitoneal administration resulted in increased liver
and lung expression (Table 1). Surprisingly, splenic expres-
sion was not statistically significant, but when examined
histologically with Bluo-gal, there was marked staining
throughout (Figure 3, A). This likely reflects splenic uptake
of -gal either hematogenously or through lymphatic chan-
nels. Similar to our findings, Thierry and colleagues28 found
splenic targeting after intraperitoneal plasmid injection.
Lipshutz and associates29 also contend that adenoviral par-
ticles are transported across the peritoneum into lymphatics
and eventually enter the systemic circulation or enter di-
rectly into peritoneal blood vessels. This would support the
liver and lung expression documented in this study. Intra-
parenchymal lung -gal staining, as well as staining lining
the surface, was found (Figure 3, D). The intraparenchymal
component probably represents hematogenous or lymphatic
uptake, whereas the surface staining is caused by direct
exposure with the vector.
Finally, the intramuscular route with adenoviral vectors
has been extensively studied by Acsadi and coworkers.30
They found prolonged muscle expression and long-term
stability with intramuscular delivery. The other theoretic
advantage with intramuscular injection is that any vector-
associated inflammation is distant from the transplanted
lung. In our study muscle and serum expression were sig-
nificantly elevated compared with that seen in control ani-
mals (P  .05), whereas lung, liver, kidney, heart, and
spleen expression were nearly identical to control values
(Table 1). As stated before, the serum expression supports
the idea that intramuscular injection effectively transfects
muscle and produces its systemic effect through release into
the bloodstream. The intramuscular approach has been
shown to be beneficial in affecting acute lung allograft
rejection, and our results support these findings.4,11
In conclusion, intratracheal gene transfer provides sig-
nificant expression in the lung with mild inflammation and
minimal systemic expression. It provides maximal lung
expression for use with gene transfer in lung transplant
models when compared with intramuscular, intravenous, or
intraperitoneal administration. This delivery strategy has
tremendous potential in experimental lung transplant mod-
els to reduce ischemia-reperfusion injury and acute allograft
rejection and should be investigated further.
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